Skip to main content

Table 1 Table giving the absolute numbers of studies investigating selected criteria (EB subtype, route of administration, outcome measure). As some studies list two possibilities for distinct criteria, respective sums might exceed the total of studies

From: Small molecule drug development for rare genodermatoses – evaluation of the current status in epidermolysis bullosa

  Publication (n = 52) Database (n = 32)
Outcome measure
Wound healing 11 24
Blister reduction 29 8
Pain 7 5
Itch 12 2
SCC 2 1
Other 7 1
Route of administration
Topical 16 21
Oral 30 9
i.v. 2 3
Local injection 6 4
Unknown 2 0
EB Subtype
EB 2 15
EBS 14 8
JEB 6 2
DEB 31 8
unknown 1 0